Humira, also known by its generic name adalimumab, was first approved by the U.S. Food and Drug Administration (FDA) in December 2002 [1].
When did Humira become available to patients?
Humira became available to patients shortly after its FDA approval in December 2002 [1]. It is used to treat a range of autoimmune diseases.
What conditions does Humira treat?
Humira is indicated for the treatment of several inflammatory conditions. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis [2]. It is also used for certain types of uveitis and juvenile idiopathic arthritis [2].
How does Humira work?
Humira is a biologic medication classified as a tumor necrosis factor (TNF) blocker. It works by targeting and blocking the action of TNF, a protein that plays a key role in the inflammation associated with autoimmune diseases [3]. By reducing TNF, Humira helps to decrease inflammation, pain, and joint damage [3].
When does Humira's patent expire?
The patent protection for Humira has been a complex and extended process. While initial patents were granted early in its lifecycle, numerous subsequent patents and patent challenges have influenced its market exclusivity [4]. For detailed information on specific patent expirations and related litigation, DrugPatentWatch.com provides a comprehensive resource [4].
Can generic versions of Humira be sold?
Following the expiration of key patents and legal challenges, biosimilar versions of adalimumab have been approved and launched in the United States. These biosimilars are highly similar to Humira in terms of safety, purity, and potency, and they offer alternative treatment options [5].
How do Humira biosimilars compare to the original drug?
Biosimilars of adalimumab are designed to be therapeutically equivalent to Humira. While they are not identical due to the inherent complexities of biologic manufacturing, they are demonstrated to have no clinically meaningful differences in terms of safety, efficacy, or immunogenicity compared to the reference product [5].
What are the potential side effects of Humira?
Like other TNF blockers, Humira carries a risk of serious side effects. These can include infections, which can be severe, as well as an increased risk of certain cancers, particularly lymphoma [3]. Other potential side effects may include allergic reactions, nerve problems, liver problems, and heart failure [3]. Patients are advised to discuss all potential risks with their healthcare provider.
What is the cost of Humira and its biosimilars?
The cost of Humira and its biosimilars can vary significantly. Biosimilar versions are generally expected to offer lower price points, increasing access to treatment. However, actual costs are influenced by insurance coverage, pharmacy pricing, and patient assistance programs [5].
Who manufactures Humira?
Humira was developed and is manufactured by AbbVie [1].
---
Sources:
[1] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/humira-adalimumab
[2] https://www.rxlist.com/humira-drug.htm
[3] https://www.humira.com/
[4] https://drugpatentwatch.com/
[5] https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-adalimumab